Australia's Prana Charging Into Confirmatory Trials For Alzheimer's Drug That Looks To Alter Disease
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Melbourne-headquartered biotech Prana is gearing up to begin confirmatory trials for its lead molecule PBT2, an Alzheimer's disease treatment that has demonstrated surprising ability to reverse dementia symptoms
You may also be interested in...
Australia’s Prana Misses Primary Endpoint In POC Alzheimer’s Disease Trial; Stock Tanks
Prana’s lead Alzheimer’s candidate fails both primary and secondary endpoints in Alzheimer’s proof-of-concept- trial, but the company still has hopes that an extension study will show a stronger signal.
Australia’s Prana Biotech Phase II Data On Huntington’s Candidate Holds Investor Interest With More To Come
Australia’s Prana Biotechnology has Phase II clinical trial data on a potential Huntington’s disease therapy to sustain a surge in the share price over the past year with more possibly on the way for an Alzheimer’s therapy.
Prospects For Pfizer/Medivation's Dimebon Dashed By Phase III Flop
The drug's inability to show an efficacy benefit highlights risks of Alzheimer's disease drug development and pressures Pfizer to pull off some pipeline wins.